Hepatitis C at a glance
- Hepatitis C is a liver infection caused by the hepatitis C virus, or HCV, and it spreads mainly through exposure to infected blood.
- Many people have no symptoms, so testing is the only reliable way to know whether infection is present.
- A reactive antibody test shows past exposure; a follow-up HCV RNA test is needed to confirm current infection.
- Modern oral antiviral treatment cures more than 95 percent of people, but treatment and follow-up must be individualized.

When liver symptoms may be urgent
Seek emergency care for vomiting blood, black or tar-like stool, severe confusion or unusual sleepiness, fainting, major shortness of breath, or rapidly increasing abdominal swelling with serious illness. These can occur with advanced liver complications or another emergency and should not wait for a routine hepatitis appointment.
Prompt assessment is also important for new yellowing of the skin or eyes, very dark urine, severe persistent vomiting, marked weakness, easy bleeding, or a significant blood exposure. A needlestick or blood-to-broken-skin exposure should be reported through the relevant medical or workplace pathway as soon as possible so baseline testing and follow-up can be arranged. There is no vaccine that prevents hepatitis C.
What hepatitis C is
Hepatitis means inflammation of the liver. Hepatitis C is caused by HCV, a bloodborne virus. The infection may be acute, meaning it began recently, or chronic, meaning the virus remains in the body. Some people clear the virus without treatment during the first months, but many develop chronic infection.
Hepatitis C is different from hepatitis A and hepatitis B. Each is caused by a different virus, has different common transmission routes, and has its own testing, prevention, and treatment approach. A person can have more than one viral hepatitis infection, so a diagnosis of one type does not exclude another.
Chronic hepatitis C can slowly scar the liver. Over years, some people develop advanced fibrosis, cirrhosis, liver failure, or liver cancer. The course varies and is affected by age, alcohol exposure, other liver disease, HIV or hepatitis B coinfection, metabolic health, and whether curative treatment is received.
Symptoms and the silent course
Most new infections cause no obvious symptoms. When symptoms occur, they may include fatigue, fever, reduced appetite, nausea, vomiting, abdominal discomfort, joint pain, dark urine, pale stool, or jaundice. These symptoms are not specific to HCV and cannot confirm the infection.
Chronic infection may remain silent for decades. A person can feel well while inflammation or scarring develops. Symptoms such as swelling, easy bruising, confusion, muscle loss, or gastrointestinal bleeding may appear only after significant liver damage. Waiting for symptoms can therefore miss the opportunity for earlier cure.
Hepatitis C can also be associated with problems outside the liver, including certain kidney, skin, blood-vessel, and metabolic conditions. These associations require clinical evaluation and should not be diagnosed from a symptom list.
How hepatitis C spreads
HCV spreads when infected blood enters another person’s bloodstream. Current transmission commonly occurs through sharing needles, syringes, or other equipment used to prepare and inject drugs. It can also occur through unsafe health procedures, unsterile tattooing or piercing equipment, and accidental occupational blood exposure.
Blood transfusion transmission has become uncommon in places that screen the blood supply, but people who received blood or organs before effective screening may have historical risk. A pregnant person with HCV can pass the virus to the baby. Sexual transmission is possible, particularly when blood exposure occurs, but risk varies with sexual practices and other infections.
HCV is not spread by hugging, sharing food, coughing, sneezing, or ordinary casual contact. People should not share razors, toothbrushes, glucose-monitoring equipment, or anything that may carry blood. Cuts should be covered. A person with HCV should not donate blood, organs, tissue, or semen unless a qualified program specifically determines eligibility.
Who should discuss testing
CDC recommends at least one hepatitis C screening test for all adults and screening during each pregnancy. Periodic testing may be recommended for people with ongoing exposures, including people who currently share injection equipment. Testing is also important after a recognized blood exposure and for people with signs of liver disease or historical risk.
These are population recommendations, not a judgment about behavior. Testing should be offered without stigma. Someone may not remember or know about a past exposure, and risk can occur in health care, household, birth, or other contexts.
Understanding the two-step testing process
The first test usually looks for antibodies to HCV. Antibodies show that the immune system has encountered the virus. A nonreactive result usually means no past exposure, although testing too soon after a recent exposure may miss infection.
A reactive antibody result does not prove that the virus is still present. Antibodies may remain after spontaneous clearance or successful treatment. A nucleic acid test for HCV RNA is needed to show current infection. Many programs use reflex testing, in which the laboratory automatically performs the RNA test on a reactive sample, reducing delays and missed follow-up.
When exposure was recent, HCV RNA can become detectable before antibodies. A clinician or exposure service can choose the appropriate timing. Home or rapid antibody tests still require follow-up RNA testing if reactive.
After current infection is confirmed, evaluation may include liver enzymes, blood counts, kidney function, assessment of liver fibrosis or cirrhosis, and testing for hepatitis B and HIV. The purpose is to plan safe treatment and follow-up, not to decide whether someone deserves care.
Treatment and cure
Direct-acting antiviral medicines, often called DAAs, can cure more than 95 percent of people, commonly with an oral course lasting about 8 to 12 weeks. Cure is confirmed by checking that HCV RNA remains undetectable after treatment. The exact regimen depends on age, pregnancy, liver status, kidney function, prior treatment, other medicines, and other clinical factors.
Treatment is recommended for nearly everyone with current infection, but this page does not select a regimen. A medication review is essential because antiviral drugs can interact with prescription medicines, over-the-counter products, supplements, and acid-reducing treatments. People should not stop or change another medicine on their own.
Being cured does not create immunity. Reinfection is possible after another exposure. Prevention and repeat testing may still matter. People with cirrhosis need ongoing liver cancer surveillance and specialist follow-up even after cure because some risk remains.
HCV treatment is not the same as treatment for hepatitis A or B. Vaccines against hepatitis A and B may be recommended for people with hepatitis C who are not already immune, because another liver infection could add risk. There is no hepatitis C vaccine.
Protecting the liver and other people
Alcohol can accelerate liver damage, so a clinician can discuss a safe plan to reduce or avoid it. People should review supplements and nonprescription medicines because some can injure the liver or interact with treatment. A balanced eating pattern, physical activity matched to ability, and management of diabetes or excess weight can support overall liver health but do not clear HCV.
Use new sterile injection equipment every time and do not share preparation equipment. Harm-reduction and substance-use treatment services can reduce infection risk without requiring someone to stop all drug use before receiving HCV care. Gloves should be used when cleaning another person’s blood, and blood spills should be handled using appropriate infection-control procedures.
Disclosure questions can be complex. HCV does not spread through normal household contact, and people should not be excluded from work, school, food preparation, or family life solely because of infection. Local laws and clinical advice can guide specific occupational or partner questions.
Pregnancy and children
Hepatitis C screening is recommended during each pregnancy. A pregnant person with current infection needs coordinated obstetric and liver care. Treatment timing depends on current evidence, medicine approvals, and individual circumstances. No one should start or stop antiviral medicine because of pregnancy without specialist guidance.
Babies exposed during pregnancy require testing on a schedule that differs from adult testing. Pediatric follow-up should be documented before discharge and communicated to the child’s care team. Breastfeeding decisions may depend on nipple bleeding and other factors, so individualized advice is appropriate.
Preparing for care
Bring any antibody and RNA results, liver test reports, imaging, treatment history, vaccination records, and a complete medicine and supplement list. Mention pregnancy possibility, alcohol use, other hepatitis or HIV testing, kidney disease, prior blood transfusions, injection or tattoo exposure, and barriers such as cost or transportation. Honest information helps care and should be met without judgment.
Ask whether the result shows past exposure or current infection, whether reflex RNA testing was completed, and how liver scarring will be assessed. Clarify the treatment goal, duration, interactions, follow-up test for cure, prevention of reinfection, and whether ongoing liver surveillance is needed.